Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsCompass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Investing News NetworkCompass Pathways to release new clinical data on psilocybin trials By Investing.com Investing.com CanadaBREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions Psychedelic AlphaCompass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials Business Wire
